The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Rates of cerebral atrophy differ in different degenerative pathologies
Open accessAbstract
Neurodegenerative disorders are pathologically characterized by the deposition of abnormal proteins in the brain. It is likely that future treatment trials will target the underlying protein biochemistry and it is therefore increasingly important to be able to distinguish between different pathologies during life. The aim of this study was to determine whether rates of brain atrophy differ in neurodegenerative dementias that vary by pathological diagnoses and characteristic protein biochemistry. Fifty-six autopsied subjects were identified with a clinical diagnosis of dementia and two serial head MRI. Subjects were subdivided based on pathological diagnoses into Alzheimer's disease, dementia with Lewy bodies (DLB), mixed Alzheimer's disease/DLB, frontotemporal lobar degeneration with ubiquitin-only-immunoreactive changes (FTLD-U), corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). Twenty-five controls were matched by age, gender and scan interval, to the study cohort. The boundary-shift integral was used to calculate change over time in whole brain (BBSI) and ventricular volume (VBSI). All BSI results were annualized by adjusting for scan interval. The rates of whole brain atrophy and ventricular expansion were significantly increased compared to controls in the Alzheimer's disease, mixed Alzheimer's disease/DLB, FTLD-U, CBD and PSP groups. However, atrophy rates in the DLB group were not significantly different from control rates of atrophy. The largest rates of atrophy were observed in the CBD group which had a BBSI of 2.3% and VBSI of 16.2%. The CBD group had significantly greater rates of BBSI and VBSI than the DLB, mixed Alzheimer's disease/DLB, Alzheimer's disease and PSP groups, with a similar trend observed when compared to the FTLD-U group. The FTLD-U group showed the next largest rates with a BBSI of 1.7% and VBSI of 9.6% which were both significantly greater than the DLB group. There was no significant difference in the rates of atrophy between the Alzheimer's disease, mixed Alzheimer's disease/DLB and PSP groups, which all showed similar rates of atrophy; BBSI of 1.1, 1.3 and 1.0% and VBSI of 8.3, 7.2 and 10.9%, respectively. Rates of atrophy therefore differ according to the pathological diagnoses and underlying protein biochemistry. While rates are unlikely to be useful in differentiating Alzheimer's disease from cases with mixed Alzheimer's disease/DLB pathology, they demonstrate important pathophysiological differences between DLB and those with mixed Alzheimer's disease/DLB and Alzheimer's disease pathology, and between those with CBD and PSP pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Cited by
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Self-citationStatistical analysis of longitudinal neuroimage data with Linear Mixed Effects models
Bernal-Rusiel, J. L., Greve, D. N., Reuter, M., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.065 · Cited by 360
A data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294
Self-citationMolecular nexopathies: a new paradigm of neurodegenerative disease
Warren, J. D., Rohrer, J. D., Schott, J. M., Fox, N. C., Hardy, J., & Rossor, M. N. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.06.007 · Cited by 265
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Whitwell, J. L., Höglinger, G. U., Antonini, A., Bordelon, Y., Boxer, A. L., Colosimo, C., van Eimeren, T., Golbe, L. I., Kassubek, J., Kurz, C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27038 · Cited by 260
Self-citationPattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies
Nedelska, Z., Ferman, T. J., Boeve, B. F., Przybelski, S. A., Lesnick, T. G., Murray, M. E., Gunter, J. L., Senjem, M. L., Vemuri, P., Smith, G. E., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.005 · Cited by 155
Self-citationEFNS task force: the use of neuroimaging in the diagnosis of dementia
Filippi, M., Agosta, F., Barkhof, F., Dubois, B., Fox, N. C., Frisoni, G. B., Jack, C. R., Johannsen, P., Miller, B. L., Nestor, P. J., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03859.x · Cited by 141
Self-citationBernal-Rusiel, J. L., Reuter, M., Greve, D. N., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.049 · Cited by 125
“…et al., 2003; Martensson et al., 2012; Paviour et al., 2006; Rosas et al., 2011; Sabuncu et al., 2011; Sluimer et al., 2008; Wenger et al., 2011; Whitwell et al., 2007; Wilde et al., 2012), employs subject-level summary measures (e.g. the annualized difference between two time-points, the slope…”
BackgroundMethodInfluentialHall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
Neuroimaging characteristics of dementia with Lewy bodies
Mak, E., Su, L., Williams, G. B., & O’Brien, J. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt248 · Cited by 120
Longitudinal diffusion tensor imaging in frontotemporal dementia
Mahoney, C. J., Simpson, I. J. A., Nicholas, J. M., Fletcher, P. D., Downey, L. E., Golden, H. L., Clark, C. N., Schmitz, N., Rohrer, J. D., Schott, J. M., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24296 · Cited by 101
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies
Sarro, L., Senjem, M. L., Lundt, E. S., Przybelski, S. A., Lesnick, T. G., Graff-Radford, J., Boeve, B. F., Lowe, V. J., Ferman, T. J., Knopman, D. S., et al. (2016) · Brain · doi:10.1093/brain/aww193 · Cited by 89
Self-citationBrain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
Knopman, D. S., Jack, C. R., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a71236 · Cited by 85
Self-citationMeasuring disease progression in frontotemporal lobar degeneration: A clinical and MRI study
Gordon, E., Rohrer, J. D., Kim, L. G., Omar, R., Rossor, M. N., Fox, N. C., & Warren, J. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d1a879 · Cited by 70
Longitudinal Grey and White Matter Changes in Frontotemporal Dementia and Alzheimer’s Disease
Frings, L., Yew, B., Flanagan, E., Lam, B. Y. K., Hüll, M., Huppertz, H.-J., Hodges, J. R., & Hornberger, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090814 · Cited by 69
Manera, A. L., Dadar, M., Collins, D. L., & Ducharme, S. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.102079 · Cited by 65
Hafkemeijer, A., Möller, C., Dopper, E. G. P., Jiskoot, L. C., van den Berg-Huysmans, A. A., van Swieten, J. C., van der Flier, W. M., Vrenken, H., Pijnenburg, Y. A. L., Barkhof, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150695 · Cited by 57
FTD spectrum: Neuroimaging across the FTD spectrum
Whitwell, J. L. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.05.009 · Cited by 53
Self-citationMak, E., Su, L., Williams, G. B., Watson, R., Firbank, M., Blamire, A. M., & O'Brien, J. T. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.01.017 · Cited by 51
Biomarkers in frontotemporal lobar degenerations—Progress and challenges
Hu, W. T., Trojanowski, J. Q., & Shaw, L. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.012 · Cited by 42
Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration
Kantarci, K., Nedelska, Z., Chen, Q., Senjem, M. L., Schwarz, C. G., Gunter, J. L., Przybelski, S. A., Lesnick, T. G., Kremers, W. K., Fields, J. A., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac013 · Cited by 39
Self-citationFrings, L., Mader, I., Landwehrmeyer, B. G., Weiller, C., Hüll, M., & Huppertz, H. (2012) · Human Brain Mapping · doi:10.1002/hbm.21304 · Cited by 38
Roussotte, F. F., Gutman, B. A., Hibar, D. P., Madsen, S. K., Narr, K. L., Thompson, P. M., & (ADNI), A. D. N. I. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.011 · Cited by 19
Metadata
- Authors
- Whitwell, J. L., Jack, C. R., Parisi, J. E., Knopman, D. S., Boeve, B. F., Petersen, R. C., Ferman, T. J., Dickson, D. W., & Josephs, K. A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-11-21
- Volume
- 130
- Issue
- 4
- Pages
- 1148-1158
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2138011006
- Cited by
- 170
- References
- 20
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.